Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220020/S008

Lava Liquid Embolic System (Lava LES)

Sirtex Medical, Inc. · Decision date Jul 9, 2026

FDA DECISIONP220020/S008

What did the FDA decide?

FDA records P220020/S008 as a supplement to PMA P220020, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 9, 2026.

FDA approval order statement

implementation of the Automated Viscometer for LAVA LES kinematic viscosity testing
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jul 9, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P220020/S008
Regulatory pathway
PMA supplement
Product code
QVG
Decision code
OK30
Decision date
Jul 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Embolization Agent, Vascular.

Product code
QVG
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P220020/S007 · Related supplement

    Lava Liquid Embolic System (Lava LES) and Lava Mixing Kit

  2. P220020/S005 · Related supplement

    Lava Liquid Embolic System (Lava LES) and Lava Mixing Kit

  3. P220020/S008 received

    Application receipt date recorded by FDA.

  4. P220020/S008 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P220020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220020

Product / regulatory recordCompanyPathwayDecision dateSource
Sirtex Medical, Inc.PMA supplementAug 5, 2025FDA
Sirtex Medical, Inc.PMA supplementSep 3, 2025FDA

Explore the linked device profile

Other records with product code QVG

Product / regulatory recordCompanyPathwayDecision dateSource
Instylla, Inc.PMA supplementOct 23, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA
Instylla, Inc.PMA supplementOct 21, 2026FDA
Instylla, Inc.PMA supplementSep 3, 2026FDA
Instylla, Inc.PMA supplementApr 2, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Sirtex Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
300 Unicorn Park Dr., 2nd Floor ,, Woburn, MA, 01801

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records